Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

22 Nov 2022

Abstract excerpt

The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity against characterized carbapenemase-producing Gram-negative isolates. A collection of 39 well-characterized Gram-negative isolates obtained from various clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotic Use and Resistance
Share to Antibiotics Pharmacokinetics and Efficacy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36551337
DOI: 10.3390/antibiotics11121681

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative OrganismsPMID 36551337Read ↗

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative BacteriaSemantic proximity Read ↗

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative BacteriaSemantic proximity Read ↗

In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinationsSemantic proximity Read ↗

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii IsolatesSemantic proximity Read ↗

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hopeSemantic proximity Read ↗

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?Semantic proximity Read ↗

Investigation of in-vitro efficacy of antibiotic combinations and presence of carbapenemases in multidrug-resistant Klebsiella pneumoniae isolatesSemantic proximity Read ↗

New Carbapenemase Inhibitors: Clearing the Way for the β-LactamsSemantic proximity Read ↗

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant <i>Acinetobacter baumannii</i> patient isolates with diverse resistance mechanismsSemantic proximity Read ↗

In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosaSemantic proximity Read ↗

In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.Semantic proximity Read ↗

Effects of different carbapenemase and siderophore production on cefiderocol susceptibility in Klebsiella pneumoniae.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.